Open an account

Omeros

OMER · NASDAQ

$16.55+$0.20 (+1.22%)TodayMarket closed ·
Prev close $16.35

About OMER

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. The company is headquartered in Seattle, Washington and currently employs 175 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.

Employees
175
Headquarters
Seattle, Washington
Listed
Oct 8, 2009
Sector
Health Care
Industry
Pharmaceuticals
Website
omeros.com

OMER key statistics

Market cap
1.18B
Price-earnings ratio
9.51
Dividend yield
—
Average volume
1.31M
Volume
725.16K
Open price
$16.28
High today
$16.78
Low today
$16.11
52 Week high
$21.24
52 Week low
$6.24

Omeros (OMER) at a glance

Omeros (OMER) last traded at $16.55, with a market cap of 1.18B and a price-to-earnings ratio of 9.51.

Today the stock has traded between $16.11 and $16.78. The current price is 2.7% above the day's low and 1.4% below its high.

Volume so far is 725.16K shares, below the average of 1.31M shares a day.

Over the past year Omeros has ranged from $6.24 to $21.24, and now sits 69% of the way up that range.

Omeros met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.15 per share against an estimate of -$0.2737.

The average analyst price target is $37.40, 126.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $37.40
Low
$22.22
Now
$16.55
High
$57.75

OMER earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 88.6% on average.

  1. Q3 FY24: reported -$0.56 per share against an estimate of -$0.7176
  2. Q4 FY24: reported -$0.54 per share against an estimate of -$0.7931
  3. Q1 FY25: reported -$0.58 per share against an estimate of -$0.578
  4. Q2 FY25: reported -$0.43 per share against an estimate of -$0.4906
  5. Q3 FY25: reported -$0.47 per share against an estimate of -$0.4539
  6. Q4 FY25: reported $0.98 per share against an estimate of -$0.5814
  7. Q1 FY26: reported -$0.24 per share against an estimate of -$0.4131
  8. Q2 FY26: reported $0.15 per share against an estimate of -$0.2737

OMER news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • Dylan Berman

    Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

  • Press releaseBusiness Wire

    Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

  • Vandana Singh

    Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    Omeros Corporation Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

Similar companies

Companies in the same industry as Omeros

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.